Bio&Tech Smart Capital

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

The MBVF is a collaborative effort between the U-M Medical School’s Fast Forward Medical Innovation (FFMI) program and the U-M College of Engineering’s Center for Entrepreneurship (CFE). Founded based on an initial gift from the Monroe-Brown Foundation, MBVF makes seed-stage equity investments in UM life science startup companies, typically $100,000-$300,000. This evergreen fund serves to drive the university’s world-class leadership by creating a critical pipeline between research and the biomedical innovation life cycle, resulting in broad clinical and economic impact through startups. The Fund is exclusively for biomedical startups with U-M IP. Most applicants need to successfully complete an existing U-M translational program such as Coulter, MTRAC for Life Sciences, NSF I-Corps. Companies interested in more information should consult with the Fund Manager.

As a Venture Capital Management firm founded in 2008, we've honed our expertise in Health Technologies: biotech, medical devices and digital health. Founded in 2008 by our seasoned, multi-disciplinary executive team and headquartered in Madrid and Barcelona, we are best positioned to reach most vibrant innovation hubs across Europe. We are at the intersection between… Science and Technology: We harness the power of scientific research and technological innovation to advance healthcare. Ventures and Innovation: We back visionary entrepreneurs and innovative ventures that are transforming the healthcare landscape. Digital and Healthcare: Embracing new digital technologies to enhance people's health.

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.